Key Finding
Moxibustion at ST25 and ST37 significantly reduced inflammatory markers and reversed 7 key colonic metabolites in Crohn's disease rats, primarily affecting amino acid biosynthesis and taurine metabolism pathways.
Researchers in China studied whether moxibustion (a traditional therapy that involves burning mugwort herb near acupuncture points) could help rats with Crohn's disease, a chronic inflammatory bowel condition that causes severe digestive symptoms. They created a Crohn's disease model in 24 rats and divided them into two groups: one receiving moxibustion treatment and one without treatment, plus a healthy control group. The moxibustion group received 30-minute treatments on specific acupuncture points (Tianshu/ST25 and Shangjuxu/ST37, located on the abdomen and leg) once daily for seven consecutive days. The results showed significant improvements in the treated rats. They gained more weight, had reduced disease severity scores, and showed less intestinal inflammation and damage compared to untreated rats. Blood tests revealed lower levels of inflammatory chemicals (TNF-α, IL-1β, and IFN-γ) after moxibustion. The researchers also analyzed colon tissue and found that moxibustion helped restore normal metabolic balance by correcting abnormal levels of various amino acids and other metabolic compounds. These metabolic changes affected important biological pathways related to immune function and inflammation. This study suggests that moxibustion may help protect the intestines in Crohn's disease by reducing inflammation and correcting metabolic imbalances, potentially helping maintain a healthier immune system in the gut. If you're considering acupuncture or moxibustion for digestive conditions, consult with a licensed acupuncturist experienced in treating inflammatory bowel disorders.
This animal study examined moxibustion effects on Crohn's disease using a TNBS-induced rat model (n=24 CD rats, n=12 controls). The treatment group received bilateral ST25 and ST37 moxibustion for 30 minutes daily over 7 days. Results demonstrated statistically significant improvements (P<0.05) in body weight, disease activity index scores, and histopathological damage. Serum inflammatory markers (TNF-α, IL-1β, IFN-γ) decreased significantly post-intervention. NMR spectroscopy and OPLS-DA analysis identified 16 differential colonic metabolites between model and control groups. Moxibustion reversed 7 key metabolites including hypoxanthine, leucine, lysine, isoleucine, betaine, tyrosine, and taurine, primarily affecting phenylalanine/tyrosine/tryptophan biosynthesis and taurine metabolism pathways. The mechanism appears to involve metabolic regulation and inflammatory modulation to maintain intestinal immune homeostasis. This provides metabolomic evidence supporting moxibustion's therapeutic effects on inflammatory bowel disease through multi-pathway metabolic correction.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Mild moxibustion at ST25 and ST36 significantly reduced visceral hypersensitivity and intestinal inflammation in PI-IBS rats by increasing beneficial gut bacteria and modulating NLRP6 inflammasome signaling pathways.
📌 Moxibustion at ST25 reduced Crohn's disease intestinal inflammation by downregulating p53 protein expression and enhancing the SLC7A11/GSH/GPX4 pathway to prevent ferroptosis and lipid peroxidation.
📌 Mild moxibustion reduced ulcerative colitis inflammation in rats by activating the non-neuronal cholinergic system to release acetylcholine, which suppressed inflammatory markers through α7 nicotinic acetylcholine receptors.